Figure 3

Improvement of spontaneous alternation performance on Y-maze task using an Aβ(1–42)-infused mouse model injected with carprofen co-incubated with Aβ(1–42) monomer by ICV. (a) The overall experimental scheme displaying the time course of sample incubation followed by the schematic brain region to show the ICV injection site of ICR mice (male, 7-week-old, n = 5/group) to create an Aβ(1–42)-infused mouse model, with reduced cognitive behavioral performance, for a Y-maze test. (b) The percentage of spontaneous alternations and (c) the number of entries observed on four Aβ(1–42)-infused ICR mice groups. The prepared groups are as following: vehicle (white, n = 5), Aβ(1–42) aggregates (0.05 nmole in PBS, black, n = 5), in addition to carprofen (0.5 or 50 μM) co-treated with Aβ(1–42) monomer (0.05 nmole in PBS, red, n = 5/group), All data represent the mean ± SEM and the statistical analyses were performed by one-way analysis of variance with the comparison to 2-day Aβ(1– 42) aggregates-treated group (black) (*P < 0.05, **P < 0.01, ***P < 0.001, other comparisons not significant). ICV, intracerebroventricular; ICR, imprinting Control Region; Car, carprofen.